A study was conducted to determine the 52-week efficacy and safety of lerodalcibep in patients with cardiovascular disease receiving LDL-C-lowering treatment.

Cholesterol is crucial for cell building and hormone production, yet high LDL levels pose heart disease risks. Misconceptions ...

USA: Single measurements of non–HDL cholesterol (non–HDL-C) and LDL cholesterol (LDL-C) taken between 18 and 30 years of age ...

At the lesion level, very intensive lipid-lowering therapy induced substantially greater percent atheroma volume regression than described in previous vessel-level analyses. Compared with statin ...

2024 年欧洲心脏病学会年会（2024 ESC）于 8 月 30 日～9 月 2 日在英国伦敦盛大召开。本届大会的主题聚焦于「个性化心血管护理」，旨在通过个性化的治疗、风险预测、护理标准定义的更新，以改善患者预后。在此次盛会中，备受瞩目的 ...

The topline results come from the phase 3 V-MONO study, which met its primary end points of percentage change in LDL-C from baseline to day 150 compared with both a placebo and with ezetimibe.

Women had their hsCRP, LDL-C and Lp(a) levels tested in a blood sample obtained when they enrolled in the WHS. The primary endpoint of the study was a first major adverse cardiovascular event ...

A new potentially druggable functional binding pocket was identified on the PCSK9 C-terminal domain (CTD), and multiple fragment screens generated a single CTD-binding hit.

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that ...

Ezetimibe is the most commonly used nonstatin agent, which lowers LDL-C levels by 13% to 20%. Wednesday, Novartis AG NVS released topline results from twice-yearly Leqvio (inclisiran) in the Phase ...

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...